iPS-ML-IFNb

iPS-ML-IFNb is an experimental cell therapy consisting of human induced pluripotent stem (iPS) cell-derived myeloid cell lines (iPS-ML) that have been genetically modified to produce interferon-beta (IFN-β). These cells are designed to function similarly to macrophages, exhibiting phagocytic ability and expressing macrophage surface markers. Upon administration, they infiltrate tumor tissues, such as metastatic melanoma, and locally secrete IFN-β. This local production of type I interferon inhibits tumor growth and promotes an anti-tumor immune environment, characterized by the increased expression of CD169, a marker for M1 macrophages that can activate anti-tumor immunity. This approach aims to overcome the logistical challenges of adoptive cell transfer by providing a scalable source of therapeutic immune cells for treating metastatic cancers.

Other names

human iPS cell-derived myeloid cell lines producing interferon-betaiPS-ML-IFN-beta